Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 524-531

  Belli, Luca Saverio ^a   Berenguer, Marina ^b   Cortesi, Paolo Angelo ^c   Strazzabosco, Mario ^d   Rockenschaub, Susanne Rasoul ^e   Martini, Silvia ^f   Morelli, Cristina ^g   Donato, Francesca ^h   Volpes, Riccardo ⁱ   Pageaux, Georges Philippe ^j   Coilly, Audrey ^k   Fagiuoli, Stefano ^l   Amaddeo, Giuliana ^m   Perricone, Giovanni ^a   Vinaixa, Carmen ^b   Berlakovich, Gabriela ^e   Facchetti, Rita ^c   Polak, Wojciech ⁿ   Muiesan, Paolo ^o   Duvoux, Christophe ^m  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF VIENNA   (Austria)

^f CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁱ Mediterranean Institute for Transplantation   (Italy)

^j HÔPITAL SAINT ELOI   (France)

^k HÔPITAL PAUL BROUSSE   (France)

^l PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^m HENRI MONDOR HOSPITAL   (France)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

Cirrhosis; Delisting; Direct acting antivirals; HCV; Liver transplantation

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; BILIRUBIN; CREATININE; DACLATASVIR; DIURETIC AGENT; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BRAIN DISEASE; CHILD PUGH SCORE; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; PROTHROMBIN TIME; TREATMENT DURATION; VIRAL CLEARANCE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR;

CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; WAITING LISTS;

EID: 84977527153     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.010     Document Type: Article

References (12)

1. [1] Manns, M., Samuel, D., Gane, E., Mutimer, D., Mc Caughan, G., Buti, M., et al. Ledipasvir and sofosbuvir plus ribavirin is patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis, 2016 (Epub ahead of print).
2. [2] Afdhal N, Everson GT, Calleja JL, McCaughan G, Bosch J, Denning J, et al. Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension. 2015 International Liver Congress: 50th Annual Meeting of the European Association of the Study of the Liver (EASL) 2015; Abstract LP13.
3. [3] Foster, G.R., Irving, W., Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., et al. Impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
4. [4] Poordad, F., Schiff, E.R., Vierling, J.M., Landis, C., Fontana, R.J., Yang, R., et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 study. J Hepatol 62 (2015), S261–S262.
5. [5] Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, Verna EC, Bhanja S, et al. Efficay and safety of grazoprevir and elbasivir in hepatitis C genotype 1 infected patients with CP class B cirrhosis. (C-SALT PART A). 2015 International Liver Congress: 50th Annual Meeting of the European Association of the Study of the Liver (EASL) 2015; Abstract O 08.
6. [6] Curry, M.P., Forns, X., Chung, R.T., Terrault, N.A., Brown, R. Jr, Fenkel, J.M., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107.
7. [7] Ruiz, I., Feray, C., Pawlotsky, J.M., Hezode, C., Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transplant 21 (2015), 408–409.
8. [8] Gray, R., A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988), 1141–1154.
9. [9] Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
10. [10] Contal, C., O'Quigley, J., An application of change-point methods in studying the effect of age on survival in breast cancer. Comput stat Data Anal 30 (1999), 253–270.
11. [11] Jang, J.W., Choi, J.Y., Kim, Y.S., Woo, H.I., Choi, S.K., Lee, C.H., et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus–related cirrhosis. Hepatology 61 (2015), 1809–1820.
12. [12] Burra, P., Germani, G., Adam, R., Karam, V., Marzano, A., Lampertico, P., et al. Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes J Hepatol 58 (2013), 287–296.